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Abstract
Background: Epigenetics has been known to play a critical role in regulating the malignant phenotype. This study
was designed to examine the expression of DOT1L (histone 3 lysine 79 methyltransferase) and H3K79 methylation
in normal ovarian tissues and ovarian tumors and to explore the function of DOT1L and its underline mechanisms
in ovarian cancer.
Methods: The expression of DOT1L and H3K79 methylation in 250 ovarian tumor samples and 24 normal ovarian
samples was assessed by immunohistochemistry. The effects of DOT1L on cell proliferation in vitro were evaluated
using CCK8, colony formation and flow cytometry. The DOT1L-targeted genes were determined using chromatin
immune-precipitation coupled with high-throughput sequencing (ChIP-seq) and ChIP-PCR. Gene expression levels
were measured by real-time PCR and immunoblotting. The effects of DOT1L on tumor growth in vivo were
evaluated using an orthotopic ovarian tumor model.
Results: DOT1L expression and H3K79 methylation was significantly increased in malignant ovarian tumors. High
DOT1L expression was associated with International Federation of Gynecology and Obstetrics (FIGO) stage,
histologic grade, and lymphatic metastasis. DOT1L was an independent prognostic factor for the overall survival
(OS) and progression-free survival (PFS) of ovarian cancer, and higher DOT1L expression was associated with poorer
OS and PFS. Furthermore, DOT1L regulates the transcription of G1 phase genes CDK6 and CCND3 through H3K79
dimethylation; therefore, blocking DOT1L could result in G1 arrest and thereby impede the cell proliferation in vitro
and tumor growth in vivo.
Conclusions: Our findings first demonstrate that DOT1L over-expression has important clinical significance in
ovarian cancer and also clarify that it drives cell cycle progression through transcriptional regulation of CDK6 and
CCND3 through H3K79 methylation, suggesting that DOT1L might be potential target for prognostic assessment
and therapeutic intervention in ovarian cancer.
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Background
Ovarian cancer (OC) is the fourth most common cause
of cancer-related deaths in women, with an estimated
200,000 cases and 125,000 deaths occurring annually
worldwide [1, 2]. Despite current advances in surgery
and adjuvant chemotherapy, the clinical outcome of pa-
tients with OC remains uncertain, with the 5-year sur-
vival rate being ~30% for advanced-stage disease. The
poor survival rate is largely attributed to the poor under-
standing of the OC initiation and progression [3]. The
discovery of novel biomarkers with high sensitivity and
specificity for the early diagnosis and target therapies of
OC will help to improve the prognosis of this disease.
Epigenetic changes, such as DNA methylation and
histone post-translational modifications, are major con-
tributing factors for carcinogenesis [4]. Given that epi-
genetic changes are reversible, there is a hope that
reversing epigenetic malfunction in cancer cells could
render them normal, launching a new and rapidly
expanding field of cancer epigenetic therapeutics [5].
Disruptor of telomeric silencing-1-like (DOT1L), a hu-
man homologue of DOT1 in yeast, is the only histone
methyltransferase that produces methylated H3K79
(H3K79mex, x = 1, 2, or 3). Globally, H3K79 methylation
is enriched in actively transcribing genes [6]. In addition
to transcription, Dot1 plays an important role in cell
cycle regulation and the DNA damage response [7]. Re-
cent studies have revealed that DOT1L is involved in the
initiation and maintenance of mixed lineage leukemia
(MLL)-rearranged leukemia, by associating with MLL fu-
sion partner proteins, e.g., AF4, AF9, AF10, or ENL,
resulting in abnormal H3K79 methylation and overex-
pression of a number of MLL target genes (e.g., HoxA9
and Meis1) [8–10]. Consequently, DOT1L is a drug tar-
get for MLL-rearranged leukemia [11, 12]. Furthermore,
a few recent publications have reported that DOT1L
plays crucial roles not only in leukemia, but also in solid
tumors, such as breast cancer, esophageal squamous cell
carcinoma, colorectal cancer, prostate cancer, and gastric
cancer [13–19]. Moreover, DOT1L inhibitors have
shown effective suppression of proliferation, migration,
and invasion of breast cancer [20].
To date, the potential role of DOT1L and its malig-
nancies in OC have not been assessed. In this study, the
prognostic significance of DOT1L expression in OC for
clinicopathological parameters and patient survival was
evaluated. Moreover, it is very significant that we identi-
fied DOT1L as a promising therapeutic target for OC
both in vitro and in vivo experiments.
Methods
Patients and samples
A total of 274 formalin-fixed paraffin-embedded tissue
samples were included in this study, comprising 24
normal ovarian tissues, 15 benign ovarian tumor, 7 bor-
derline ovarian tumor, and 228 malignant ovarian tumor
samples. These samples were obtained from patients di-
agnosed with ovarian carcinoma who underwent intitial
surgery at the Gynecology Department of Huazhong
University of Science and Technology Affiliated Tongji
Hospital from 2003 to 2013. The tissue samples were
obtained with informed consent from patients. None of
the patients had any prior history of chemoradiation, ra-
diation, or hormonal therapy before the surgery. Clinical
information of the patients’ was recorder in detail, and
the diagnoses were confirmed by at least two patholo-
gists. The histopathologic subtypes of the 7 borderline
ovarian tumor and 228 malignant ovarian tumor samples
included 211 serous cystadenocarcinomas, 5 mucinous
cystadenocarcinomas, 12 endometrioid adenocarcin-
omas, 4 ovarian germ-cell tumors, 2 ovarian clear-cell
carcinomas, and 1 ovarian transitional cell carcinoma.
There were 20 cases in stage I, 17 cases in stage II, 159
cases in stage III, 29 cases in stage IV, and 10 cases
remained unknown, according to the International
Federation of Gynecology and Obstetrics (FIGO) staging
system. With regard to histological grading, 40 cases had
grade 1, 58 cases had grade 2, 120 cases had grade 3,
and 17 cases remained unknown. The median age of pa-
tients (16–80 years old) was 54 years old. Among the
235 OC tissues, the total of 206 cases has been followed
up. The present study was with the approval and sup-
port of the Ethics or Institutional Review Board of
Tongji Hospital.
Immunohistochemistry
Formalin-fixed, paraffin-embedded tissue blocks were
retrieved from the archive and were analyzed by IHC de-
scribed previously [21]. In short, The Avidin-Biotin
Complex (ABC) Vectastain Kit (Zsgb-Bio, Beijing,
China) was used and the DOT1L polyclonal antibody
(1:250; ab64077; Abcam), H3K79me2 polyclonal anti-
body (1:200; ab3594; Abcam), cyclin D3 antibody (1:100;
ab63535; Abcam), and the CDK6 polyclonal antibody
(1:500; GTX103992; GeneTex) were used as primary
antibodies incubated with tissue sections (2 mm) after
heat-induced epitope retrieval (10 mM sodium citrate
buffer of pH 6.0), followed by incubation with a secondary
antibody conjugated to peroxidase (1:100; Dako). Detec-
tion was performed using diaminobenzidine for 8 min,
and the slides were counterstained with hematoxylin.
The scoring system that was used incorporated both
the intensity of the scoring (0 = absent, 1 = weak, 2 =
moderate, 3 = strong) and the percentage of positive
tumor cells (0 = 0%, 1 = 1–25%, 2 = 26–50%, 3 = 51–
75%, 4 = 76–100%). Points for the intensity and the
percentage of staining were added and assigned as overall
score according to Kamat and M. Caroline [22, 23]. Two
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investigators scored all slides for DOT1L and H3K79
methylation staining and followed the criterions of
double-blind trials. Based on the overall score, the DOT1L
and H3K79 methylation staining results were classified
into low expression (≤4) and high expression (>4).
Cells and transfection
Human epithelial ovarian cell lines SK-OV-3, TOV21G,
OV90, and CaOV3 were purchased from the American
Type Culture Collection (Manassas, VA, USA). SK-OV-3
and CaOV3 were cultured in McCoy’s 5A Medium
(Boster, Wuhan, China), while TOV21G and OV90 in
mixed MCDB105 Medium (Sigma-Aldrich Co., St Louis,
MO, USA) and M199 Medium (Gibco, Invitrogen,
Carlsbad, CA, USA) (1:1) supplemented with 10% fetal
bovine serum (Gibco, Invitrogen, Carlsbad, CA, USA)
and 1% penicillin/streptomycin at 37 °C in a humidified
atmosphere of 5% CO2 and 95% air. The cells were
transduced with CMV-Fluc-IRES-RFP lentiviral particles
(GeneChem, Shanghai, China). RFP/luciferase-expressing
cells were isolated by FACS and used in living imaging.
ShDOT1L-1 and shDOT1L-2 shRNA lentiviral parti-
cles (GeneChem) were used to knock-down DOT1L
expression, targeting 5′-CGGATCTCAAGCTCGCT
AT-3′ and 5′-AGTGCTCGAATTGAGAGAA-3′, re-
spectively. ShCON, the short hairpin RNA (shRNA)
not targeting any known gene, was used as control.
SK-OV-3 and TOV21G cells were transduced with
DOT1L shRNA lentiviral particles, or control shRNA
lentiviral particles. The cells with stable transfection
were selected with puromycin.
Assay of gene expression by real-time RT-PCR
Total RNA was isolated using Trizol (Invitrogen,
Carlsbad, CA). RT-PCR analysis was carried out in a
CFX96 Touch™ Real-Time PCR Detection system (Bio-
Rad Laboratories, Inc., Hercules, CA, USA) and iQ™
SYBR®Green Supermix (Bio‑Rad Laboratories, Inc.,
Hercules, CA, USA), which contained 5 ng complemen-
tary DNA (cDNA) and 10 pM of each primer. The pri-
mer sequences used for PCR are shown in Additional
file 1: Table S1. The relative messenger RNA (mRNA ex-
pression) levels were normalized to that of glyceralde-
hyde 3-phosphate dehydrogenase (GAPDH). The PCR
protocol is as follows: denaturation at 95 °C for 10 min;
40 cycles of denaturation at 95 °C for 10 sec; annealing
at 60 °C for 30 sec; and extension at 72 °C for 30 sec.
Each sample was assayed in triplicate, and relative
mRNA expression levels were calculated using the △△Ct
method.
Western blot analysis
Western blot assay was performed following the proto-
col as previously described [24, 25]. Briefly, the cells
were harvested and lysed using ice-cold RIPA lysis buffer
(50 mM Tris-HCl (pH 7.4), 150 mM sodium chloride,
1% Nonidet P-40, and 0.5% sodium deoxycholate). Fol-
lowing centrifugation at 10,000×g for 15 min at 4 °C, the
proteins in the supernatants were quantified by Bradford
method and separated using 10% SDS-PAGE gel and
electrotransferred from the gel to a nitrocellulose
membrane (Merck & Co., Inc., Whitehouse Station,
NJ, USA). Following blocking with 5% skimmed milk
in phosphate-buffered saline, the membranes were
immunoblotted with the primary antibodies, namely,
CDK6 (GeneTex, San Antonio, Texas, USA), DOT1L,
H3, H3K79me2, cyclin D3, and GAPDH (Abcam,
Cambridge, UK) at 4 °C overnight. Specifically bound
HRP-conjugated secondary antibodies were detected
using an ECL detection system (ChemiDocTM XRS+
machine, Bio-Rad Laboratories). Protein levels of GAPDH
and H3 were employed as loading controls. Densitometric
analyses were performed using ImageJ software. Relative
quantification was carried out after normalization to the
band intensities of GAPDH or H3. A Mann-Whitney test
was performed to assess the difference of protein expres-
sion between groups. Each experiment was performed in
triplicate and repeated at least 3 times.
In vitro cell viability
Cell proliferation was evaluated using a colorimetric
assay as described previously [26]. Cell viability was
measured by a commercially Cell Counting Kit (CCK-8,
Beyotime Institute of Biotechnology, China). The indi-
cated cells were seeded into 96-well plates at a density of
104 cells per well. The drugs were added when the plates
were seeded. After incubation for 3, 6, 9, and 12 days,
cell proliferation in 96-well plates was measured and
10 μL CCK-8 reagent was added to each well and incu-
bated at 37 °C for 4 h. Absorbance was measured at
450 nm by using a spectrophotometer. Each experiment
was performed in triplicate and repeated at least 3 times.
Colony formation assay
The colony formation assay was performed on the indi-
cated cells. For each group, 800 survived cells/well were
incubated in 6-well plates, containing 2.5 ml complete
medium per well, followed by incubation for 10 days. At
the indicated time point, cells were washed twice with
PBS, treated with crystal violet for 10 min, washed, then
counted, and measured. All the experiments were per-
formed at least 3 times. The colonies with >40 cells were
subsequently counted under a phase contrast micro-
scope at ×40 magnification.
Cell cycle and cell apoptosis analyses
Cell cycle and cell apoptosis analyses were determined
by flow cytometry (BD, UA) [27, 28]. In this experiment,
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the SK-OV-3 and TOV21G cells were treated with
10 μM SGC0946 and EPZ004777 for 12 days, respect-
ively. Then, the cells treated above were harvested and
washed with phosphate-buffered saline (PBS). For cell
cycle analysis, the pellets were fixed with ice-cold 70%
ethanol overnight at 4 °C. Cell pellets were then sus-
pended in 300 μl PBS containing 100 μg/ml RNase for
30 min at room temperature, and then 10 μg/ml propi-
dium iodide (Sigma-Aldrich Co., St Louis, MO, USA).
The distribution of cells in the different phases of the
cell cycle was analyzed from DNA histograms using BD
Cell Quest software (Becton Dickinson Biosciences, San
Diego, CA, USA). For cell apoptosis analysis, cells were
resuspended in 500 μl binding buffer (Annexin V-FITC/
PI Apoptosis Detection Kit (BD Biosciences)), containing
5 μl of annexin V-fluorescein isothiocyanate (FITC)
stock and 5 μl of 20 μg/ml PI for determination of phos-
phatidylserine (PS) exposure on the outer plasma mem-
brane. After incubation for 10 min at room temperature
in a light-protected area, the cells were quantified by
flow cytometry. Viable cells were annexin V- and PI-
negative.
ChIP-qPCR and ChIP-Seq
ChIP assays were performed following the protocols as
previously described [13, 29, 30]. In brief, crosslinking
was performed with 1% formaldehyde at room tem-
perature for 10 min and the reaction was stopped by
treatment with 0.125 M glycine. The cell pellets were re-
suspended in 200 ml of SDS lysis buffer and sonicated
using a Bioruptor (Cosmo Bio Co. Ltd, Tokyo, Japan).
The cell lysates were then immunoprecipitated with spe-
cific antibodies overnight at 4 °C and further incubated
with salmon sperm DNA coupled to protein A-agarose
(Millipore) for 2 h at 4 °C. The precipitates were washed,
eluted, and then reverse-crosslinked with 20 ml 5 M
NaCl by incubating at 65 °C overnight. DNA fragments
were precipitated from the eluate and dissolved in
ddH2O. Eluted DNA fragments were analyzed by qPCR,
or subjected to sequencing using next-generation Solexa
sequencing.
Animal studies
Female NOD-SCID mice (4 weeks old) were purchased
from Beijing HFK Bio-Technology Co. Ltd. (Beijing,
China). The studies were approved by the Committee on
Ethics of Animal Experiments of Tongji Medical
College. The mice were maintained in the accredited
animal facility of Tongji Medical College. Upon injection
of SK-OV-3 cells transduced with CMV-Fluc-IRES-RFP
lentiviral particles into the ovarian bursa bilaterally of
female mice, we have developed an orthotopic ovarian
tumor model. SGC0946 (10 mg/kg per mouse) was
administered intraperitoneal twice a week for 6 weeks.
The size of tumor was monitored in living mice by
optical imaging of luciferase activity using the IVIS
Spectrum system (Caliper, Xenogen, USA). After
anaesthetization with 3% pentobarbital sodium, mice
were imaged 10 min after intraperitoneal injection of
100 mg/kg D-luciferin. In the experimental metastasis
model [31, 32], tumor cells were injected into mice
via the tail vein (2 × 106 cells/mouse). At each time
option, mice were monitored using the IVIS SPECTRUM
system according to the method above. Total flux
(photons/s) was quantified using Living Image version
4.3.1 software.
Statistical analysis
Chi-squared tests were used to evaluate whether DOT1L
expression was correlated with clinicopathological fac-
tors of OC. Overall survival (OS) and progression-free
survival (PFS) curves were plotted using the Kaplan-
Meier analysis followed by two-sided log-rank tests. The
univariate and multivariate Cox proportional hazards
modeling was used to evaluate prognostic significance.
For cell-based assays, differences between groups were
assessed by two sided Student’s t tests, unless indicated
otherwise. Data were analyzed using SPSS 18.0 statistic
software (SPSS Inc., Chicago, IL). Each experiment was
repeated at least 3 times with comparable results, unless
indicated otherwise. Significance was assessed at the
level of P < 0.05. (*P < 0.05, **P < 0.01, and ***P < 0.001,
****P < 0.0001).
Results
DOT1L and H3K79 methylation expression in normal
ovarian tissues and benign, borderline, and malignant
ovarian tumors
Immunohistochemical staining for DOT1L (Fig. 1a)
and H3K79 methylation (Additional file 2: Figure S1a)
expression was performed on 24 normal ovarian tis-
sues, 15 benign ovarian tumors, 7 borderline ovarian
tumors, and 228 malignant ovarian tumors. At the
time of analysis, 94 (45.6%) of the 206 evaluable pa-
tients had died and 131 (63.6%) of the 206 evaluable
patients had experienced disease progression, resulting
in a median OS of 36 months (95% CI, 24.5 to
47.5 months) and median PFS of 30 months (95% CI,
25.1 to 34.9 months). The average length of follow-up
time for the 112 patients still alive was 38.5 months
(range, 10 to 81 months). The percentage of high
DOT1L expression was 14.6% in normal ovarian tissues,
23.4% in benign ovarian tumors, 21.5% in borderline
ovarian tumors, and increased to 57.5% in malignant
ovarian tumors (normal vs. malignant, P < 0.0001; be-
nign vs. malignant, P = 0.012; borderline vs. malignant,
P = 0.082; normal vs. benign, P = 0.69; normal vs. border-
line, P = 0.62; benign vs. borderline, P = 1.00) (Fig. 1b).
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Similarly, H3K79 methylation was significantly increased
in malignant ovarian cancer with 59.3% of high H3K79
methylation, while normal ovarian tissues with 16.65%,
benign ovarian tumors with 16.65%, and borderline ovar-
ian tumors with 37.75% (normal or benign vs. malignant,
P < 0.0001; borderline vs. malignant, P = 0.0045; nor-
mal or benign vs. borderline, P = 0.0014) (Additional file 2:
Figure S1b).
Association between DOT1L expression and
clinicopathological parameters of OC
To clarify the potential prognostic roles of DOT1L in
OC development and progression, we evaluated the as-
sociation of DOT1L expression with various clinical fea-
tures of 235 cases of OC, including 7 borderline ovarian
tumors and 228 malignant ovarian tumors (Table 1).
High expression of DOT1L was associated with FIGO
stage (P = 0.001), histologic grade (P = 0.012), and lymph
node metastasis (P = 0.036). However, there was no sig-
nificant association between DOT1L expression and pa-
tients’ age (P = 0.729), ascites (P = 0.944), and level of
preoperative CA125 (P = 0.176) (Table 1).
High expression of DOT1L as an independent prognostic
marker of OC
We used only 228 malignant ovarian tumor samples for
survival analysis. The Kaplan-Meier survival analysis in-
dicated that OC patients with high expression of DOT1L
exhibited a significantly reduced OS (P < 0.001, Fig. 1c)
and PFS (P < 0.001, Fig. 1d) than those with low expres-
sion. In addition, we determined prognostic factors of
OS and PFS using the univariate (Additional file 3:
Table S2) and multivariate (Table 2) Cox regression
model. The results identified high expression of
DOT1L (P < 0.001), and age (P = 0.002) as prognostic
factors of OS independent of other clinicopathological
factors (Table 2). Meanwhile, the results identified
high expression of DOT1L (P < 0.001), age (P = 0.005),
and level of preoperative CA125 (P < 0.001) as prog-
nostic factors of PFS independent of other clinico-
pathological factors (Table 2). Taken together, these
results suggest that DOT1L expression was signifi-
cantly increased in malignant ovarian tumors. Higher
DOT1L expression was associated with advanced
FIGO stage, poor histopathological grade, and lymph
Fig. 1 DOT1L protein expression in human ovarian tissues and Kaplan-Meier plots. a Immunohistochemical staining of DOT1L protein in human
ovarian tissues. A brown color in cancer cells is considered as a positive staining. Negative control without first antibody is performed in the normal
ovarian tissue. Representative images of DOT1L expression in normal ovarian tissues and benign, borderline, and malignant ovarian tumors are shown.
Original magnification ×100 and ×400. Scale bar 100 and 25 μm, respectively. b The case rate of DOT1L high and low expression. For comparison
between two groups, χ2 test was applied. c Overall survival (OS) rate in patients with high DOT1L expression was significantly lower than in patients
with no or low DOT1L expression. d Progression-free survival (PFS) rate in patients with high DOT1L expression was significantly lower than in patients
with no or low DOT1L expression
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node metastasis of OC patients. Importantly, DOT1L
expression was identified as an independent prognos-
tic factor for OC.
Knocking down of DOT1L inhibits the proliferation of
ovarian cancer cells and induces G1 phase arrest
Given the fact that DOT1L has strong correlation with
malignant behavior of ovarian cancer, such as late FIGO
stage and poor histologic grade, a loss-of-function ap-
proach was applied to explore the function of DOT1L.
First, we detected the expression levels of DOT1L in
various OC cell lines by Western blot (Fig. 2a). SK-OV-3
and TOV21G cells have a relatively high expression of
DOT1L compared with the other cell lines; therefore, we
chose these two cell lines to knock down DOT1L. Suc-
cessful knockdown by shDOT1L shRNA lentiviral parti-
cles was verified by RT-PCR (Fig. 2b) and Western blot
(Fig. 2c). It was worth to note that the level of
H3K79me2 was reduced responding to knockdown of
DOT1L protein expression. To determine if knock-down
of DOT1L expression by shRNA could lead to a de-
crease in the proliferation and survival of OC cells,
CCK8 and colony formation assay were performed. The
OD450 values of the SK-OV-3 and TOV21G cells trans-
fected with shDOT1L shRNAs lentiviral particles
showed significant decrease (all P < 0.05), compared with
those cells in the control groups (Fig. 2d). The colony
formations of transfected SK-OV-3 and TOV21G cells
were also significantly reduced compared with the con-
trol groups (all P < 0.05, Fig. 2e). Consistent with knock-
down of DOT1L expression genetically using shRNA,
the proliferation and survival of OC cells were also
reduced by inhibition of DOT1L enzymatic activity
pharmacologically with EPZ004777 and SGC0946 treat-
ment (Fig. 2f and g). SGC0946 was capable of inhibiting
the growth of both SK-OV-3 and TOV21G cells in a
dose- and time-dependent manner (Fig. 2f ). Both
EPZ004777 and SGC0946 could reduce the colony for-
mation rate of SK-OV-3 and TOV21G cells (Fig. 2g). In
order to evaluate the therapeutic effects of DOT1L
Table 1 Association of DOT1L expression with the
clinicopathological features of patients with borderline and
malignant ovarian tumors





Age at diagnosis 235 0.120 0.729
≤50 114 51 (44.7%) 63 (55.3%)
>50 117 55 (47.0%) 62 (53.0%)
Unknown 4
FIGO stage 235 17.655 0.001
I 20 18 (90.0%) 2 (10.0%)
II 17 8 (47.1%) 9 (52.9%)
III 159 66 (41.5%) 93 (58.5%)
IV 29 11 (37.9%) 18 (62.1%)
Unknown 10
Histologic grade 235 8.831 0.012
Grade 1 40 27 (67.5%) 13 (32.5%)
Grade 2 58 24 (41.4%) 34 (58.6%)
Grade 3 120 50 (41.7%) 70 (58.3%)
Unknown 17
Ascites 235 0.005 0.944
Yes 173 78 (45.1%) 95 (54.9%)
No 36 16 (44.4%) 20 (55.6%)
Unknown 26
LN metastasis 235 4.392 0.036
Yes 73 29 (39.7%) 44 (60.3%)





≤600 68 33 (48.5%) 35 (51.5%)
>600 80 30 (37.5%) 50 (62.5%)
Unknown 87
Table 2 Multivariate Cox regression analysis of the clinicopathogical parameters for overall survival and progression free survival
Overall survival Progression free survival
HR 95% CI P HR 95% CI P
FIGO stage (early stage vs. advanced stage) 1.127 0.357–3.562 0.838 1.744 0.576–5.288 0.325
Histologic grade (well vs. poor and moderate) 0.615 0.256–1.475 0.276 0.904 0.393–2.077 0.811
Ascites (no vs. yes) 0.850 0.381–1.897 0.692 0.667 0.337–1.323 0.247
LN metastasis (no vs. yes) 0.924 0.460–1.856 0.823 0.786 0.410–1.506 0.468
Age (≤50 vs. >50 years) 2.920 1.466–5.815 0.002 2.403 1.302–4.435 0.005
Preoperative CA125 (U/ml) (≤600 vs. >600) 0.548 0.280–1.073 0.079 0.327 0.177–0.607 0.000
DOT1L expression (low vs. high) 4.705 2.160–10.248 0.000 8.884 3.974–19.861 0.000
HR hazard ratio, CI confidence interval
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inhibitors on a larger ovarian cancer cell line panel in
vitro, we chose OV90 and CaOV3, which could repre-
sent high-grade serous ovarian cancer for CCK8 and col-
ony formation assay [33]. Intriguingly, SGC0946 was
capable of inhibiting the growth of both OV90 and
CaOV3 cells in a dose- and time-dependent manner
(Additional file 2: Figure S1c). Both EPZ004777 and
SGC0946 could reduce the colony formation rate of
OV90 and CaOV3 cells (Additional file 2: Figure S1d).
To further determine the reason that knockdown
DOT1L inhibits ovarian cancer cell proliferation, we
next performed flow cytometric analysis of apoptosis
and cell cycle. None effect of DOT1L on apoptosis of
either SK-OV-3 or TOV21G cells was seen after treat-
ment with EPZ004777 and SGC0946 for up to 12 days
(Fig. 3a, b). However, EPZ004777 and SGC0946 treat-
ment induced increased G1 population and decreased S
phase and G2/M phase cells in asynchronized SK-OV-3
Fig. 2 Knocking down of DOT1L inhibits the proliferation of ovarian cancer cells. a Western blot analysis of DOT1L expression in various ovarian
cancer cell lines. GAPDH was used as loading control. b RT-PCR analysis of endogenous DOT1L mRNA expression in SK-OV-3 and TOV21G cells
that were transfected with shRNAs lentiviral articles against DOT1L as indicated in the figure. The shRNAs were able to knockdown DOT1L. c Western
blot analysis of SK-OV-3 and TOV21G cells transfected with shDOT1L shRNAs. The blot was probed with DOT1L and H3K79me2 antibodies. GAPDH and
H3 were used as loading control. d The cell proliferation of SK-OV-3 and TOV21G was determined by CCK-8 assay after shDOT1L shRNAs transfection
(n = 3). The results are representative of three independent experiments. P < 0.05. e The colony formation assay was performed in SK-OV-3 and TOV21G
cells after shDOT1L shRNAs transfection (n = 3). Representative images (left) and the histogram (right) of three independent experiments were shown.
P < 0.05. f SK-OV-3 and TOV21G cells were seeded in 96-well plates and cultured in the presence of SGC0946 at variable concentrations (0, 0.2, 2, or
20 μM) for up to 12 days. Then, the OD450 values of corresponding cells were measured at 0, 3, 6, 9, and 12 days after SGC0946 treatment. The results
are representative of three independent experiments. (n = 3, P < 0.05). g The colony formation assay was performed in SK-OV-3 and TOV21G cells after
10 μM EPZ004777 and 10 μM SGC0946 treatment for up to 12 days. Representative images (left) and the histogram (right) of three independent
experiments were shown. (n = 3, P < 0.05)
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and TOV21G cells (Fig. 3c, d, Additional file 4: Figure S2).
Similar result was seen in both SK-OV-3 and TOV21G
cells transfected with DOT1L shRNA lentivirus
(GeneChem) (Additional file 5: Figure S3). These re-
sults demonstrate that blocking DOT1L in ovarian
cancer could result in G1 arrest and thereby impede
the cell proliferation in vitro.
DOT1L regulates the transcription of G1 arrest genes
CDK6 and CCND3 through H3K79 dimethylation
Given that knocking down of DOT1L could inhibit the
proliferation of ovarian cancer cells in vitro and induce
G1 arrest as mentioned above, we then proceeded to
elucidate the molecular mechanism underlying this
phenomenon. To identify genes regulated by DOT1L in
ovarian cancer cells, we performed chromatin immune-
precipitation coupled with high-throughput sequencing
(ChIP-seq) analysis using ChIP-grade DOT1L antibody
in SK-OV-3 cells. The proportion of DOT1L peaks was
8.60% distributed in promoters, 3.20% in exons, 39.60%
in introns, and 48.6% in intergenics (Fig. 4a). The
average distribution of DOT1L-bound peaks near TSS
was shown in Fig. 4b. We then examined the change of
expression in mRNA level of primary genes involved in
G1 arrest responding to knocking down of DOT1L in
OC cells. These primary G1 arrest genes include D-type
cyclins (D1, D2, and D3), cyclin E, and Cdks (2, 4,
and 6) [29, 30]. Downregulation of CCND3 and
CDK6 were seen in SK-OV-3 cells and TOV21G cells
both by DOT1L shRNAs silicing and treated with DOT1L
inhibitors (Fig. 4c, d, Additional file 6: Figure S4a and b).
However, we could not detect the change of other G1 ar-
rest genes. Interestingly, among these downregulated
genes responding to DOT1L-knockdown, we found the
intron of CDK6 and CCND3 genes were bound to
DOT1L, suggesting that CDK6 and CCND3 genes were
the direct target genes of DOT1L (Additional file 7). To
verify whether DOT1L directly regulated the transcription
of CDK6 and CCND3 through the H3K79 dimethylation,
we performed ChIP-PCR using ChIP-grade antibodies for
DOT1L and H3K79me2, targeting the detected binding
sites nearby with three different primer sets. In ac-
cordance with the results above, CDK6 levels in
DOT1L-immunoprecipitants were decreased by more
than 12 times in the shDOT1L transfected SK-OV-3
cells compared with the control (P < 0.0001, Student’s
t test), and an approximately 5-fold decrease of CDK6
was observed in the H3K79me2-enriched cell lysates
(P < 0.0001, Student’s t test) (Fig. 4e). Likewise, we ob-
served a decrease in the CCND3 levels by near 13 times
in the DOT1L-immunoprecipitants of the lysates from
shDOT1L transfected SK-OV-3 cells (P < 0.0001, Student’s
t test), and by more than 4 times decrease in the
H3K79me2-immunoprecipitants (P < 0.0001, Student’s
Fig. 3 Effect of blocking DOT1L in the cell apoptosis and cell cycle. After exposure to 10 μM EPZ004777 and SGC0946 seperately for 12 days in
both SK-OV-3 and TOV21G cells, cell apoptosis and cell cycle analyses in each group were determined by flow cytometry. a The typical images
and b the proportion of apoptosis cell were measured in SK-OV-3 and TOV21G cells. The proportion of cell cycle distribution in SK-OV-3 cells (c)
and in TOV21G cells (d) was shown. Columns are the mean of triplicate samples
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t test) (Fig. 4f ).Similar results were seen in TOV21G
cells (Additional file 6: Figure S4). We further con-
firmed downregulation of CDK6 and cyclin D3 in
both SK-OV-3 and TOV21G cells knockdown of
DOT1L at the protein level, which are critical for
normal G1 phase progression [34, 35] (Fig. 5). These
results support that blocking DOT1L can result in G1
arrest through its H3K79 dimethylation activity.
Effect of inhibition of DOT1L pharmacologically on tumor
progression in vivo
To determine whether DOT1L has a functional role in
tumor progression in vivo, we used a mouse orthotopic
xenograft ovarian cancer model. Mice treated with
SGC0946 displayed obviously slower progress in tumor
growth compared with the mice untreated (Fig. 6a).
After the sacrifice of these mice, tumor masses were re-
moved and weighted. The size and weight of tumor
masses treated with SGC0946 were significantly smaller
than the untreated group (Fig. 6b). We performed RT-
PCR analysis for CDK6 and CCND3 on these tumor
masses. CDK6, as well as CCND3, was significantly de-
creased in SGC0946-treated group than the untreated
group (Fig. 6c, d). Representative IHC images for
H3K79me2, CDK6, and cyclin D3 in the mice were shown
to confirm the inhibition of DOT1L enzymatic activity
upon SGC0946 treatment, showing impeded H3K79me2,
CDK6, and cyclin D3 levels in the tumors (Fig. 6e, f ).
Taken together, these results demonstrated that DOT1L
inhibitors could inhibit tumor growth in vivo.
Fig. 4 DOT1L regulates the transcription of G1 arrest genes CDK6 and CCND3 through H3K79 dimethylation. a Genomic distribution of DOT1L
ChIP-seq peaks in SK-OV-3 cells. The proportion of DOT1L peaks was 8.60% distributed in promoters, 3.20% in exons, 39.60% in introns, and 48.6%
in intergenics. b The average distribution of DOT1L-bound peaks near TSS. c and d RT-PCR detecting the change of primary G1 arrest genes,
D-type cyclins (D1, D2, and D3), cyclin E, Cdks (2, 4, and 6) in mRNA levels in SK-OV-3 cells knocking down of DOT1L with shDOT1L shRNAs
lentiviral particles (c) and DOT1L inhibitors, EPZ004777 and SGC0946 (d) (P < 0.05, Student’s t test, data represented as mean±SD). e and f DOT1L
transcriptionally regulates the expression of CDK6 (e) and CCND3 (f) through induction of H3K79 dimethylation in the binding regions of these
genes. Chromatin immunoprecipitation (ChIP) PCR assays were performed in a loss-of-function system. SK-OV-3 cells were transfected with
shDOT1L shRNAs and shCON lentiviral particles and ChIP assays using anti-DOT1L and anti-H3K79me2 antibodies were performed with ChIP
primers targeting the binding regions of CDK6 and CCND3 (P < 0.05, Student’s t test, data represented as mean±SD)
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Discussion
This is the first study to examine DOT1L expression
and H3K79 methylation in ovarian cancer. In human,
DOT1L is involved in the oncogenesis of several
leukemia subtypes, mostly characterized by chromo-
somal translocations involving the mixed lineage
leukemia (MLL) gene [36]. To identify the role of
DOT1L in ovarian cancer, we performed immunohisto-
chemistry and found that DOT1L expression was signifi-
cantly increased in malignant ovarian cancer. In
addition, H3K79 methylation was also significantly in-
creased in malignant ovarian cancer, indicating the cor-
relation of DOT1L and H3K79 methylation in ovarian
cancer. Higher DOT1L expression was associated with
advanced FIGO stage, poor histopathological grade, and
lymph node metastasis of OC patients. Importantly,
DOT1L expression was identified as an independent
prognostic factor for OC, which raised the possibility
that DOT1L might be correlated with malignant
behavior of ovarian cancer. As expected, our in vitro
experiment demonstrated that blocking DOT1L in ovar-
ian cancer could lead to the decrease of ovarian cancer
cell viability and colony-forming ability.
DOT1L has a critical role in regulating gene transcrip-
tion, development, cell cycle progression, somatic repro-
gramming, and DNA damage repair [37–39]. Consistent
with previous finding that DOT1L siRNA-transfected
human lung cancer cells undergo G1 cell cycle arrest
[40], we showed here that knocking down of DOT1L in
ovarian cancer cells could result in G1 arrest and there-
fore impede the cell proliferation. It is worth mentioning
that asynchronized cells were used for cell cycle analysis
in this paper, due to the reason that DOT1L might be
related with DNA replication [38, 39]. Most importantly,
the present study provides mechanistic insight into the
inhibition of ovarian cancer cell proliferation by blocking
DOT1L via downregulation of CDK6 and CCND3
through H3K79 dimethylation, providing a novel mech-
anism of epigenetic regulation of DOT1L-mediated tran-
scription of cell cycle genes. The D-type cyclins (cyclins
Fig. 5 Knocking down of DOT1L decreases the expression of CDK6 and cyclin D3 in ovarian cancer cells. Western blotting confirmed decrease of
corresponding G1 arrest proteins, CDK6, and cyclin D3 protein levels in SK-OV-3 cells and TOV21G cells knocking down of DOT1L with shDOT1L
shRNAs (a) and DOT1L inhibitor, SGC0946 (b). c and d Densitometric analysis of the Western blot. Data shown are mean±SD and a two-tailed
Mann-Whitney test was used for statistical analysis (P < 0.05). GAPDH or H3 was loading as control
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D1, D2, and D3) are the first cyclins to be induced as
cells enter the G1 phase of the cell cycle [34, 41, 42]. D-
type cyclins associate with and activate cyclin-dependent
kinases (CDK), such as CDK4 and CDK6 [34]. Specially,
cyclin D3 was identified as a direct target of Notch1 that
promotes cell-cycle progression and proliferation both in
peripheral and leukemic T cells [43]. The data presented
in this report demonstrated that DOT1L regulation of
cell cycle was through CDK6 and CCND3. Although
several studies reported that some histone modifications
transcriptionally regulated the expression of cell cycle
regulators such as CDK inhibitors to govern cell cycle
progression [40, 44, 45], in fact, our data together with
the described molecular functions identified CDK6 and
cyclin D3 as transcriptionally regulated genes by
DOT1L. Given the fact that the cell-cycle arrest network
is complex, because the regulators involved act redun-
dantly, have multiple substrates, and provide feedback
control [46], the phenomenon was explainable.
The dynamic interplays among different chromatin
post-transcription modifications control gene expression
and provide novel opportunities for targeted combin-
ation therapies in multiple cancer types. Molecular tar-
geting of specific histone methyltransferase is emerging
as a new direction for cancer therapy [47]. Of the known
histone methyltransferase enzymes, DOT1L is a promis-
ing target due to it being the only known H3K79 histone
methyltransferase, its unique non-SET catalytic domain,
and its role in promoting and maintaining MLL
leukemogenesis [48, 49]. It is interesting to note that
small molecule DOT1L inhibitors have been recently de-
veloped, and one of the DOT1L inhibitors is already
under investigation in a phase I clinical trial in patients
with MLL fusion gene-driven leukemia [37]. Fortunately,
our data showed that inhibition of DOT1L enzymatic
activity with EPZ004777 and SGC0946 treatment could
suppress ovarian cancer cell proliferation in vitro, and
furthermore, administration of SGC0946 in vivo resulted
Fig. 6 Effect of inhibition of DOT1L pharmacologically on tumor progression in vivo. After orthotopic transplantation of tumors performed by
SK-OV-3 cells transduced with CMV-Fluc-IRES-RFP lentiviral particles, BALB/c-nude mice were treated with SGC0946 (10 mg/kg body weight) or
vehicle control twice a week for 6 weeks by intraperitoneal injection. The size of tumor was closely monitored by three-dimensional reconstruction
of in vivo bioluminescence images. a The representative images (left) were shown and tumor size (right) was calculated (n = 9 per group, P < 0.05,
Student’s t test, data represented as mean±SD). b The mice were sacrificed after being monitored using the IVIS SPECTRUM system. Photograph of
tumor masses (left) was shown and the tumor weight (right) was measured (n = 9 per group, P < 0.05, Student’s t test, data represented
as mean±SD). RT-PCR was performed on the tumor masses from the mice mentioned above to analyze the expression of CDK6 (c) and
CCND3 (d). GAPDH was used as a loading control. e Representative IHC images for H3K79me2, CDK6, and cyclin D3 in the mice were
shown. f The positive cells of H3K79me2, CDK6, and cyclin D3 were measured
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in significant inhibition of tumor progression in the
ovarian orthotopic xenograft mice model. Consequently,
DOT1L could have strong prospects for therapeutic tar-
get in ovarian cancer.
Conclusions
Our findings first demonstrated that OC patients ex-
pressing high level of DOT1L have poorer OS and PFS
compared with those with low DOT1L expression, and
DOT1L expression can be regarded as an independent
prognostic factor. Furthermore, DOT1L regulates the
transcription of G1 phase genes CDK6 and CCND3
through H3K79 dimethylation, thereby knocking down
of DOT1L could result in G1 arrest and therefore im-
pede the cell proliferation and tumor progression both
in vitro and in vivo. Our results suggest that DOT1L
might be potential target for prognostic assessment and
therapeutic intervention in ovarian cancer.
Additional files
Additional file 1: Table S1. The primer sequences used for PCR.
(DOCX 15 kb)
Additional file 2: Figure S1. Immunostaining of H3K79 methylation in
human ovarian cancer specimens and effects of DOT1L inhibitors in vitro.
(a) Immunohistochemical staining of H3K79 methylation in human
ovarian tissues. A brown color in cancer cells is considered as a positive
staining. Negative control without first antibody is performed in the
normal ovarian tissue. Representative images of H3K79 methylation in
normal ovarian tissues and benign, borderline, and malignant ovarian
tumors are shown. Original magnification ×100 and ×400. Scale bar
100 μm and 25 μm, respectively. (b) The case rate of H3K79 methylation
high and low expression. For comparison between two groups, χ2 test
was applied. (c) OV90 and CaOV3 cells were seeded in 96-well plates and
cultured in the presence of SGC0946 at variable concentrations (0, 0.2, 2,
or 20 μM) for up to 12 days. Then the OD450 values of corresponding
cells were measured at 0, 3, 6, 9, and 12 days after SGC0946 treatment.
The results are representative of three independent experiments. (n = 3,
P < 0.05). (d) The colony formation assay was performed in OV90 and
CaOV3 cells after 10 μM EPZ004777 and 10 μM SGC0946 treatment for
up to 12 days. The histogram of three independent experiments was
shown. (n = 3, P < 0.05). (TIF 5990 kb)
Additional file 3: Table S2. Univariate Cox regression analysis of the
clinicopathogical parameters for overall survival and progression free
survival. (DOCX 17 kb)
Additional file 4: Figure S2. Effect of blocking DOT1L in cell cycle.
After exposure to 10 μM EPZ004777 and SGC0946 seperately for 12 days
in both SK-OV-3 and TOV21G cells, cell apoptosis and cell cycle analyses
in each group were determined by flow cytometry. The typical images of
cell cycle in SK-OV-3 cells (a) and in TOV21G cells (b) were shown.
(TIF 713 kb)
Additional file 5: Figure S3. Effect of blocking DOT1L using shRNAs in
the cell apoptosis and cell cycle. ShDOT1L-1 and shDOT1L-2 shRNA lentiviral
particles (GeneChem) were used to knock-down DOT1L expression in both
SK-OV-3 and TOV21G cells, cell apoptosis and cell cycle analyses in each
group were determined by flow cytometry. (a) The typical images and (b)
the proportion of apoptosis cell were measured in SK-OV-3 and TOV21G
cells. The typical images (c) and the proportion of cell cycle distribution (d)
in SK-OV-3 cells were shown. The typical images (e) and the proportion of
cell cycle distribution (f) in TOV21G cells were shown. Columns are the
mean of triplicate samples. (TIF 1351 kb)
Additional file 6: Figure S4. DOT1L regulates the transcription of G1
arrest genes CDK6 and CCND3 through H3K79 dimethylation. (a) and (b)
RT-PCR detecting the change of primary G1 arrest genes, D-type cyclins
(D1, D2, and D3), cyclin E, Cdks (2, 4, and 6) in mRNA levels in TOV21G
cells knocking down of DOT1L with shDOT1L shRNAs lentiviral particles
(a) and DOT1L inhibitors, EPZ004777 and SGC0946 (b) (P < 0.05, Student’s
t test, data represented as mean±SD). (c) and (d) DOT1L transcriptionally
regulates the expression of CDK6 (c) and CCND3 (d) through induction of
H3K79 dimethylation in the binding regions of these genes. Chromatin
immunoprecipitation (ChIP) PCR assays were performed in a loss-of-
function system. TOV21G cells were transfected with shDOT1L shRNAs
and shCON lentiviral particles, and ChIP assays using anti-DOT1L and
anti-H3K79me2 antibodies were performed with ChIP primers targeting
the binding regions of CDK6 and CCND3 (P < 0.05, Student’s t test, data
represented as mean±SD). (TIF 815 kb)
Additional file 7: Possible target genes of DOT1L analyzed from DOT1L
ChIP-seq. (XLSX 854 kb)
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